As of today (2026-06-26), the Forward Annual Dividend Yield of Bafna Pharmaceuticals is 0.00%.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Bafna Pharmaceuticals is 0.00%.
NSE:BAFNAPH's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.08 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Bafna Pharmaceuticals Forward Dividend Yield % Related Terms
NSE:BAFNAPH vs ZTS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bafna Pharmaceuticals and its competitors. According to the industry distribution chart, Bafna Pharmaceuticals ranks #999999 out of 504 companies in the Drug Manufacturers industry.
Is Bafna Pharmaceuticals' Forward Dividend Yield % too high?
Bafna Pharmaceuticals' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Bafna Pharmaceuticals ranks #999999 out of 504 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Forward Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #999999 out of 504 companies for Forward Dividend Yield %. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 2.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.08, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.56, compared to a current price of ₹194.68 — trading 115% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.56.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Forward Dividend Yield %: 0.00%
GF Value™: ₹90.56 vs. price of ₹194.68 (115% above fair value)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score
Get the complete analysis for NSE:BAFNAPH
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 